ProQR Therapeutics N.V. (PRQR)
PRQR Stock Price Chart
Explore ProQR Therapeutics N.V. interactive price chart. Choose custom timeframes to analyze PRQR price movements and trends.
PRQR Company Profile
Discover essential business fundamentals and corporate details for ProQR Therapeutics N.V. (PRQR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Sept 2014
Employees
166.00
Website
https://www.proqr.comCEO
Daniel Anton de Boer
Description
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQR Financial Timeline
Browse a chronological timeline of ProQR Therapeutics N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.14, while revenue estimate is $4.56m.
Earnings released on 12 May 2026
EPS came in at -$0.15 matching the estimated -$0.15, while revenue for the quarter reached $2.35m , missing expectations by -54.73%.
Earnings released on 12 Mar 2026
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $5.54m , missing expectations by -16.41%.
Earnings released on 6 Nov 2025
EPS came in at -$0.12 falling short of the estimated -$0.10 by -20.00%, while revenue for the quarter reached $3.41m , missing expectations by -44.20%.
Earnings released on 7 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.08 by -75.00%, while revenue for the quarter reached $4.49m , missing expectations by -18.16%.
Earnings released on 8 May 2025
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $4.95m , beating expectations by +3.10%.
Earnings released on 13 Mar 2025
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $4.46m , missing expectations by -18.10%.
Earnings released on 7 Nov 2024
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $4.21m , missing expectations by -39.81%.
Earnings released on 8 Aug 2024
EPS came in at -$0.03 surpassing the estimated -$0.12 by +75.00%, while revenue for the quarter reached $6.81m , missing expectations by -43.41%.
Earnings released on 9 May 2024
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $4.81m , beating expectations by +70.48%.
Earnings released on 13 Mar 2024
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $3.52m , missing expectations by -79.81%.
Earnings released on 7 Nov 2023
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $1.45m , missing expectations by -88.58%.
Earnings released on 3 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $1.31m , missing expectations by -23.13%.
Earnings released on 16 May 2023
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $712.12k , missing expectations by -49.85%.
Earnings released on 29 Mar 2023
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $885.43k , missing expectations by -13.19%.
Earnings released on 9 Nov 2022
EPS came in at -$0.34 falling short of the estimated -$0.23 by -47.83%, while revenue for the quarter reached $933.60k , beating expectations by +13.55%.
Earnings released on 4 Aug 2022
EPS came in at -$0.22 surpassing the estimated -$0.26 by +15.38%, while revenue for the quarter reached $1.07m , beating expectations by +18.44%.
Earnings released on 5 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $1.36m , beating expectations by +53.68%.
Earnings released on 24 Feb 2022
EPS came in at -$0.30 falling short of the estimated -$0.26 by -15.38%, while revenue for the quarter reached $270.96k , missing expectations by -68.42%.
Earnings released on 4 Nov 2021
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%, while revenue for the quarter reached $1.01m , beating expectations by +261.47%.
Earnings released on 5 Aug 2021
EPS came in at -$0.29 falling short of the estimated -$0.26 by -11.54%, while revenue for the quarter reached $288.31k , beating expectations by +20.13%.
PRQR Stock Performance
Access detailed PRQR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
